>Tried the same for BEAM, hoping to jog my memory
and while I can see similar run up,
Pat,
While doing my due dilly on SNRS, I went into DJ Interactive
library. Here's what I have for BEAM on a P/R 7/18/95:
"BEAM shares have been strong recently on perception
that the company is moving closer to FDA approval, said
Jonathan Cohen, analyst at SmithBarney. Cohen and most
other analysts expect Summit to receive an FDA
"approvable" letter and full approval by the end of the year."
That would also explain VISX run to $40's by year end.
Both BEAM and VISX ran up in expectation, then continued
up on actual approval.
BTW, Jon Cohen is now an analyst at Merrill Lynch. Doesn't
follow laser stocks any more, but when I read the archives,
there were a bunch of other analysts following BEAM, VISX
and SNRS. I'm sure SNRS is reappearing on many of their radar
screens.
With no real analyst coverage, SNRS will fly when a national
firm begins with a "Buy" on them, IMO.
Cheers,
Skane |
